Diabetic macular edema is a prevalent retinal disorder causing symptoms like blurry, wavy and double vision, and potentially permanent blindness. Currently, the standard of care requires frequent anti-vascular endothelial growth factor therapy. However, a large portion of patients suffer from suboptimal outcomes.
Diabetic Macular Edema (DME)
Silently blinding millions of people worldwide.
463,000,000
Worldwide diabetic population
4.6%
People with diabetes develop DME
40%
DME patients are poor anti-VEGF responders
DME, a Vascular Complication
Persistent hyperglycermia (high levels of blood sugar) tends to damage blood vessles resulting in leakage and fluid accumulation in the retina. In many cases, anti-VEGF drugs are insufficient to address extra mechanisms that destabilize blood vessels, which represents a need for novel therapeutics.
Healthy Eye
Eye with DME
Reestablish Tissue Homestasis
At the core of our technology is a proprietary protein therapeutic to reverse DME and recover healthy retina.
Retinal homeostasis represents a steady state in which pro-angiogenic and anti-angiogenic proteins counterbalance each other to reach vascular stability. In contrast, inability to maintain homeostasis drives formation and progression of the disease. We aim to replenish a critical anti-angiogenic protein and bring back homeostasis.
Healthy
DME
Anti-VEGF Therapy
Our Strategy
First-in-class protein therapy not based on anti-VEGF.
Leading the Way in Unmet DME Treatment
We focus on an endogenous anti-angiogenic protein whose production is suppressed in DME patients. Through protein engineering, we develop a long-acting therapeutic, IB-06, which inhibits not only VEGF but also other angiogenic proteins in the retina.
Clinical Relevance
IB-06 is an engineered protein derived from a crucial anti-angiogenic factor that prevents vascular leakage while the significantly lower amount has been demonstrated in patients with DME
Clinical Relevance
IB-06 is an engineered protein derived from a crucial anti-angiogenic factor that prevents vascular leakage while the significantly lower amount has been demonstrated in patients with DME
Efficient Delivery
IB-06 carries excellent stability in the vitreous so the frequency of administration is minimized
Efficient Delivery
IB-06 carries excellent stability in the vitreous so the frequency of administration is minimized
Treatment Regimen
IB-06 aims to complement anti-VEGF agents that are not effective in many DME patients
Treatment Regimen
IB-06 aims to complement anti-VEGF agents that are not effective in many DME patients
